Lymphoma  >>  tirbanibulin oral (KX2-391 oral)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
tirbanibulin oral (KX2-391 oral) / Hanmi, Athenex
NCT00646139: KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment

Completed
1
7
US
Src kinase inhibitor KX2-391, immunoenzyme technique, pharmacological study
Roswell Park Cancer Institute
Lymphoma, Lymphoproliferative Disorder, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
08/08
03/09
NCT00658970: Evaluation of KX2-391 in Patients With Advanced Malignancies

Completed
1
50
US
KX2-391
Athenex, Inc.
Solid Tumors, Lymphoma
03/10
05/11

Download Options